J9282Mitomycin intravesical inst
Published CMS Medicare Part B payment-limit context for J9282, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$274.342
per 1 MG · Medicare Part B
Down 1.4%from $278.332 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$278.8906$273.7834
2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: Not published; 2025-Q3: Not published; 2025-Q4: Not published; 2026-Q1: Not published; 2026-Q2: $278.332; 2026-Q3: $274.342
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Mitomycin ingredient family (FDA data as of August 20, 2026).
Zusduri
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Mitomycin presentations
2 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.